{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:49:57Z","timestamp":1770994197372,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1124\/dmd.112.050625","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T16:25:40Z","timestamp":1357748740000},"page":"709-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Methadone N-Demethylation by the Common CYP2B6 Allelic Variant CYP2B6.6"],"prefix":"10.1016","volume":"41","author":[{"given":"Sarah","family":"Gadel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Crafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Regina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan D.","family":"Kharasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.050625_bib1","first-page":"493","article-title":"Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1124\/dmd.112.050625_bib2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.111.039586","article-title":"Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262","volume":"39","author":"Ariyoshi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050625_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1369-1600.2010.00274.x","article-title":"CYP2B6 and OPRM1 gene variations predict methadone-related deaths","volume":"16","author":"Bunten","year":"2011","journal-title":"Addict Biol"},{"key":"10.1124\/dmd.112.050625_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.112.050625_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.110.035246","article-title":"Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin","volume":"39","author":"Chung","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050625_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050625_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050625_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.112.050625_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050625_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone\u2014metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.112.050625_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1124\/dmd.112.050625_bib12","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1124\/dmd.112.050625_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","article-title":"Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes","volume":"14","author":"Hesse","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.112.050625_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.050625_bib15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.112.050625_bib16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1124\/dmd.111.040352","article-title":"Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether","volume":"39","author":"Honda","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050625_bib17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2217\/pgs.11.96","article-title":"Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.112.050625_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.31.4.398","article-title":"Functional characterization of cytochrome P450 2B6 allelic variants","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050625_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","article-title":"Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)","volume":"116","author":"Kharasch","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.112.050625_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050625_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050625_bib22","doi-asserted-by":"crossref","unstructured":"Kharasch ED Stubbert K (2013). Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol, in press,","DOI":"10.1002\/jcph.1"},{"key":"10.1124\/dmd.112.050625_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.112.050625_bib24","doi-asserted-by":"crossref","unstructured":"Levran O Peles E Hamon S Randesi M Adelson M Kreek MJ (2011). CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol [published ahead of print]","DOI":"10.1111\/j.1369-1600.2011.00349.x"},{"key":"10.1124\/dmd.112.050625_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"10.1124\/dmd.112.050625_bib26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920009789895534","article-title":"Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6","volume":"10","author":"Mo","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.050625_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/dmd.111.039347","article-title":"Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo","volume":"40","author":"Raccor","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050625_bib28","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0b013e318238fec5","article-title":"Perioperative pharmacokinetics of methadone in adolescents","volume":"115","author":"Sharma","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.112.050625_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric metabolic interactions and stereoselective human methadone metabolism","volume":"321","author":"Totah","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.050625_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.112.050625_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/dmdi-2012-0027","article-title":"Cytochrome P450 2B6: function, genetics, and clinical relevance","volume":"27","author":"Turpeinen","year":"2012","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1124\/dmd.112.050625_bib32","doi-asserted-by":"crossref","first-page":"S491","DOI":"10.1016\/S0168-8278(11)61246-4","article-title":"Pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir","volume":"54","author":"van Heeswijk","year":"2011","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.112.050625_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugalcdep.2012.05.009","article-title":"Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers","volume":"126","author":"Vourvahis","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/dmd.112.050625_bib34","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.050625_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","article-title":"CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer","volume":"31","author":"Wang","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.112.050625_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FPC.0b013e32833bba0e","article-title":"Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22)","volume":"20","author":"Watanabe","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.112.050625_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.tpj.6500157","article-title":"Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation","volume":"3","author":"Xie","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.112.050625_bib38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1124\/dmd.111.042416","article-title":"Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo","volume":"40","author":"Xu","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050625_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.112.050625_bib40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.111.183111","article-title":"Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex","volume":"338","author":"Zhang","year":"2011","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624096892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624096892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.050625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:07:44Z","timestamp":1739905664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624096892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0090955624096892"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.050625","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methadone N-Demethylation by the Common CYP2B6 Allelic Variant CYP2B6.6","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.050625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}